Comparative Pharmacology
Head-to-head clinical analysis: FUZEON versus VALACYCLOVIR HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUZEON versus VALACYCLOVIR HYDROCHLORIDE.
FUZEON vs VALACYCLOVIR HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fusion inhibitor; binds to gp41 of HIV-1, preventing conformational changes required for fusion with host CD4+ T-cell membrane.
Valacyclovir hydrochloride is a prodrug of acyclovir. After oral administration, it is rapidly converted to acyclovir, which inhibits viral DNA polymerase, leading to chain termination and inhibition of viral DNA replication.
90 mg subcutaneously twice daily
500 mg orally twice daily for recurrent genital herpes; 1 g orally twice daily for herpes zoster; 1 g orally three times daily for herpes simplex encephalitis or immunocompromised patients.
None Documented
None Documented
Terminal elimination half-life: 3.8 hours; clinically, steady-state plasma concentrations are achieved within 2-3 days with subcutaneous administration
Terminal elimination half-life: 2.5–3.3 hours in patients with normal renal function; prolonged to 14 hours in renal impairment (CrCl 15–30 mL/min).
Renal: approximately 70% as unchanged drug via glomerular filtration; fecal: <5% as metabolites
Renal excretion: >90% as unchanged drug and inactive metabolite (9-carboxymethoxymethylguanine). Biliary/fecal: <2%.
Category C
Category A/B
Antiviral
Antiviral